Weldon JE - Search Results

1

Evaluating the influence of common antibiotics on the efficacy of a recombinant immunotoxin in tissue culture.

Zhu Y, Weldon JE. Zhu Y, et al. Among authors: weldon je. BMC Res Notes. 2019 May 27;12(1):293. doi: 10.1186/s13104-019-4337-6. BMC Res Notes. 2019. PMID: 31133049 Free PMC article.

2

A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.

Hansen JK, Weldon JE, Xiang L, Beers R, Onda M, Pastan I. Hansen JK, et al. Among authors: weldon je. J Immunother. 2010 Apr;33(3):297-304. doi: 10.1097/CJI.0b013e3181cd1164. J Immunother. 2010. PMID: 20445350 Free PMC article.

3

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, Pastan I. Onda M, et al. Among authors: weldon je. Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5742-7. doi: 10.1073/pnas.1102746108. Epub 2011 Mar 21. Proc Natl Acad Sci U S A. 2011. PMID: 21436054 Free PMC article.

4

Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.

Weldon JE, Skarzynski M, Therres JA, Ostovitz JR, Zhou H, Kreitman RJ, Pastan I. Weldon JE, et al. Bioconjug Chem. 2015 Jun 17;26(6):1120-8. doi: 10.1021/acs.bioconjchem.5b00190. Epub 2015 Jun 3. Bioconjug Chem. 2015. PMID: 25997032 Free PMC article.

5

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, Pastan I. Weldon JE, et al. Blood. 2009 Apr 16;113(16):3792-800. doi: 10.1182/blood-2008-08-173195. Epub 2008 Nov 6. Blood. 2009. PMID: 18988862 Free PMC article.

6

A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.

Weldon JE, Pastan I. Weldon JE, et al. FEBS J. 2011 Dec;278(23):4683-700. doi: 10.1111/j.1742-4658.2011.08182.x. Epub 2011 Jun 2. FEBS J. 2011. PMID: 21585657 Free PMC article. Review.

7

A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.

Liu W, Onda M, Kim C, Xiang L, Weldon JE, Lee B, Pastan I. Liu W, et al. Among authors: weldon je. Protein Eng Des Sel. 2012 Jan;25(1):1-6. doi: 10.1093/protein/gzr053. Epub 2011 Nov 17. Protein Eng Des Sel. 2012. PMID: 22101015 Free PMC article.

8

A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.

Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I. Weldon JE, et al. Mol Cancer Ther. 2013 Jan;12(1):48-57. doi: 10.1158/1535-7163.MCT-12-0336. Epub 2012 Nov 6. Mol Cancer Ther. 2013. PMID: 23136186 Free PMC article.

9

Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.

Mazor R, Vassall AN, Eberle JA, Beers R, Weldon JE, Venzon DJ, Tsang KY, Benhar I, Pastan I. Mazor R, et al. Among authors: weldon je. Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):E3597-603. doi: 10.1073/pnas.1218138109. Epub 2012 Dec 3. Proc Natl Acad Sci U S A. 2012. PMID: 23213206 Free PMC article.

10

Immunotoxins with decreased immunogenicity and improved activity.

Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R. Pastan I, et al. Leuk Lymphoma. 2011 Jun;52 Suppl 2(Suppl 2):87-90. doi: 10.3109/10428194.2011.573039. Epub 2011 Apr 19. Leuk Lymphoma. 2011. PMID: 21504287 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters